These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 11257104)
41. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR; Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536 [TBL] [Abstract][Full Text] [Related]
42. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]. Tonin PN Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226 [TBL] [Abstract][Full Text] [Related]
43. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Chen JJ; Silver D; Cantor S; Livingston DM; Scully R Cancer Res; 1999 Apr; 59(7 Suppl):1752s-1756s. PubMed ID: 10197592 [TBL] [Abstract][Full Text] [Related]
44. [Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition]. Ruiz-Flores P; Calderón-Garcidueñas AL; Barrera-Saldaña HA Rev Invest Clin; 2001; 53(1):46-64. PubMed ID: 11332051 [TBL] [Abstract][Full Text] [Related]
45. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Roa BB; Boyd AA; Volcik K; Richards CS Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191 [TBL] [Abstract][Full Text] [Related]
46. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. Peto J; Collins N; Barfoot R; Seal S; Warren W; Rahman N; Easton DF; Evans C; Deacon J; Stratton MR J Natl Cancer Inst; 1999 Jun; 91(11):943-9. PubMed ID: 10359546 [TBL] [Abstract][Full Text] [Related]
47. [From gene to disease; from BRCA1 or BRCA2 to breast cancer]. Devilee P; Tollenaar RA; Cornelisse CJ Ned Tijdschr Geneeskd; 2000 Dec; 144(53):2549-51. PubMed ID: 11191790 [TBL] [Abstract][Full Text] [Related]
48. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252 [TBL] [Abstract][Full Text] [Related]
49. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. Grzybowska E; Zientek H; Jasinska A; Rusin M; Kozlowski P; Sobczak K; Sikorska A; Kwiatkowska E; Gorniak L; Kalinowska E; Utracka-Hutka B; Wloch J; Chmielik E; Krzyzosiak WJ Hum Mutat; 2000 Dec; 16(6):482-90. PubMed ID: 11102977 [TBL] [Abstract][Full Text] [Related]
50. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers. Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318 [TBL] [Abstract][Full Text] [Related]
51. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Welcsh PL; King MC Hum Mol Genet; 2001 Apr; 10(7):705-13. PubMed ID: 11257103 [TBL] [Abstract][Full Text] [Related]
52. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800 [TBL] [Abstract][Full Text] [Related]
53. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591 [TBL] [Abstract][Full Text] [Related]
54. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Vahteristo P; Eerola H; Tamminen A; Blomqvist C; Nevanlinna H Br J Cancer; 2001 Mar; 84(5):704-8. PubMed ID: 11237395 [TBL] [Abstract][Full Text] [Related]
55. Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Kadouri L; Kote-Jarai Z; Easton DF; Hubert A; Hamoudi R; Glaser B; Abeliovich D; Peretz T; Eeles RA Int J Cancer; 2004 Jan; 108(3):399-403. PubMed ID: 14648706 [TBL] [Abstract][Full Text] [Related]
56. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Antoniou AC; Durocher F; Smith P; Simard J; Easton DF; Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652 [TBL] [Abstract][Full Text] [Related]
57. Genetic susceptibility to breast cancer. Mavaddat N; Antoniou AC; Easton DF; Garcia-Closas M Mol Oncol; 2010 Jun; 4(3):174-91. PubMed ID: 20542480 [TBL] [Abstract][Full Text] [Related]
58. The influence of familial and hereditary factors on the prognosis of breast cancer. Chappuis PO; Rosenblatt J; Foulkes WD Ann Oncol; 1999 Oct; 10(10):1163-70. PubMed ID: 10586331 [TBL] [Abstract][Full Text] [Related]
59. Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs. Li N; Rowley SM; Thompson ER; McInerny S; Devereux L; Amarasinghe KC; Zethoven M; Lupat R; Goode D; Li J; Trainer AH; Gorringe KL; James PA; Campbell IG Breast Cancer Res; 2018 Jan; 20(1):3. PubMed ID: 29316957 [TBL] [Abstract][Full Text] [Related]
60. Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hughes DJ Fam Cancer; 2008; 7(3):233-44. PubMed ID: 18283561 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]